At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CR crane
Pre-Mkt 06-05 05:31:34 EDT
188.36
+2.27
+1.22%
High189.95Low186.38Vol348.62K
Open186.98D1 Closing186.09Amplitude1.92%
Mkt Cap10.85BTradable Cap9.19BTotal Shares57.60M
T/O65.60MT/O Rate0.71%Tradable Shares48.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
GlobeNewswire  ·  06-03 10:47
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
Crane Is Maintained at Buy by DA Davidson
Dow Jones  ·  06-02
Crane Is Maintained at Buy by DA Davidson
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
GlobeNewswire  ·  06-01
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
GlobeNewswire  ·  06-01
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
GlobeNewswire  ·  05-29
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
prnewswire  ·  05-28
PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
GlobeNewswire  ·  05-22
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
GlobeNewswire  ·  05-22
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
GlobeNewswire  ·  05-22
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
GlobeNewswire  ·  05-22
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
GlobeNewswire  ·  05-21
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Dow Jones  ·  05-15
Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
Dow Jones  ·  05-14
Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
GlobeNewswire  ·  05-14
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
GlobeNewswire  ·  05-13
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
GlobeNewswire  ·  05-13
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
Press Release: Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Dow Jones  ·  05-13
Press Release: Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Cellectis Reports Financial Results for the First Quarter 2026
GlobeNewswire  ·  05-12
Cellectis Reports Financial Results for the First Quarter 2026
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
GlobeNewswire  ·  05-06
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
Crane director Susan D. Lynch acquires $26,607 of common shares
Reuters  ·  05-02
Crane director Susan D. Lynch acquires $26,607 of common shares

Introduction

Company Name.
crane
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.
Issue price:
--